Evidence map›Paper›PMID 42183606›Full record

ArticleClinical pharmacology and therapeutics2026

Bemnifosbuvir: An HCV NS5B Inhibitor With Multiple Modes of Action.

Carolin Zitzmann, Ruy M Ribeiro, Aurélien Marc, Xiao-Jian Zhou, Alan S Perelson

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Carolin ZitzmannTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico, USA.ORCID 0000-0001-5188-0042
Ruy M RibeiroTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico, USA.ORCID 0000-0002-3988-8241
Aurélien MarcTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico, USA.ORCID 0000-0002-6936-5388
Xiao-Jian ZhouAtea Pharmaceuticals, Inc., Boston, Massachusetts, USA.ORCID 0009-0009-7662-1616
Alan S PerelsonTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico, USA.ORCID 0000-0002-2455-0002

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bemnifosbuvir (BEM) is a potent, pan-genotypic inhibitor targeting the hepatitis C virus (HCV) NS5B polymerase. Its antiviral activity was evaluated in an ascending dose phase I clinical trial involving 30 patients treated once a day for 7 days. After treatment initiation, plasma HCV RNA declined in a biphasic manner with a mean reduction of 2.3 log

Indexed as

Antiviral AgentsHepacivirusUridine MonophosphateViral Nonstructural ProteinsAlanine TransaminaseDose-Response Relationship, DrugFemaleHumansMaleRNA-Dependent RNA PolymeraseRNA, ViralAlanine TransaminaseAntiviral AgentsNS-5 protein, hepatitis C virusRNA-Dependent RNA PolymeraseRNA, ViralUridine MonophosphateViral Nonstructural Proteins

Identifiers

PMID42183606
PMCPMC13339047

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.